Autoimmune Hypoglycemia occurs when blood glucose (sugar) levels drop below normal levels. Glucose levels are considered low under 70 mg/dL. Autoimmune hypoglycemia is characterized by elevated levels of insulin in the presence of endogenous anti-insulin antibodies with insulin or anti-insulin receptor antibodies. Hypoglycemia is frequently seen in individuals with diabetes but is also commonly found in people who have insulin resistance, however is rarely documented outside of the Asian demographic. Symptoms include dizziness, headache, pale color, confusion, and in severe cases, seizures. Immediate treatment includes raising blood sugar levels and long term treatments include monitoring symptoms and blood sugar levels.
Autoimmune Hypoglycemia Bioinformatics Tool
Laverne is a handy bioinformatics tool to help facilitate scientific exploration of related genes, diseases and pathways based on co-citations. Explore more on Autoimmune Hypoglycemia below!
For more information on how to use Laverne, please read the How to Guide.
We have 1450 products for the study of Autoimmune Hypoglycemia that can be applied to Western Blot, Chromatin Immunoprecipitation, Flow Cytometry, Immunohistochemistry, Immunocytochemistry/Immunofluorescence from our catalog of antibodies and ELISA kits.
Autoimmune Hypoglycemia is also known as Autoimmune Hypoglycaemia.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.